Download MendeleyLead optimization of 2-hydroxymethyl imidazoles as non-hydroxamate LpxC inhibitors: Discovery of TP0586532.
Ushiyama, F., Takashima, H., Matsuda, Y., Ogata, Y., Sasamoto, N., Kurimoto-Tsuruta, R., Ueki, K., Tanaka-Yamamoto, N., Endo, M., Mima, M., Fujita, K., Takata, I., Tsuji, S., Yamashita, H., Okumura, H., Otake, K., Sugiyama, H.(2020) Bioorg Med Chem 30: 115964-115964
- PubMed: 33385955
- DOI: https://doi.org/10.1016/j.bmc.2020.115964
- Primary Citation of Related Structures:
7DEL, 7DEM, 7DEN - PubMed Abstract:
Infectious diseases caused by resistant Gram-negative bacteria have become a serious problem, and the development of therapeutic drugs with a novel mechanism of action and that do not exhibit cross-resistance with existing drugs has been earnestly desired. UDP-3-O-acyl-N-acetylglucosamine deacetylase (LpxC) is a drug target that has been studied for a long time. However, no LpxC inhibitors are available on the market at present. In this study, we sought to create a new antibacterial agent without a hydroxamate moiety, which is a common component of the major LpxC inhibitors that have been reported to date and that may cause toxicity. As a result, a development candidate, TP0586532, was created that is effective against carbapenem-resistant Klebsiella pneumoniae and does not pose a cardiovascular risk.
Organizational Affiliation:
Taisho Pharmaceutical Co., Ltd, 1-403 Yoshino-Cho, Kita-Ku, Saitama 331-9530, Japan. Electronic address: f-ushiyama@taisho.co.jp.
